| Third-line targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium JC Wells, I Stukalin, C Norton, S Srinivas, JL Lee, F Donskov, ... European urology 71 (2), 204-209, 2017 | 86 | 2017 |
| The lung immune prognostic index discriminates survival outcomes in patients with solid tumors treated with immune checkpoint inhibitors DE Meyers, I Stukalin, IA Vallerand, RT Lewinson, A Suo, M Dean, ... Cancers 11 (11), 1713, 2019 | 61 | 2019 |
| Contemporary treatment of metastatic renal cell carcinoma I Stukalin, N Alimohamed, DYC Heng Oncology Reviews 10 (1), 2016 | 53 | 2016 |
| Conditional survival of patients with metastatic testicular germ cell tumors treated with first-line curative therapy JJ Ko, B Bernard, B Tran, H Li, T Asif, I Stukalin, M Lee, D Day, ... Journal of Clinical Oncology 34 (7), 714-720, 2016 | 50 | 2016 |
| Synchronous versus metachronous metastatic disease: impact of time to metastasis on patient outcome—results from the International Metastatic Renal Cell Carcinoma Database … F Donskov, W Xie, A Overby, JC Wells, AP Fraccon, CS Sacco, C Porta, ... European urology oncology 3 (4), 530-539, 2020 | 39 | 2020 |
| Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium I Stukalin, JC Wells, J Graham, T Yuasa, B Beuselinck, C Kollmansberger, ... Current Oncology 26 (2), 175-179, 2019 | 35 | 2019 |
| Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials CL Gan, I Stukalin, DE Meyers, S Dudani, HAI Grosjean, S Dolter, ... European Journal of Cancer 151, 115-125, 2021 | 28 | 2021 |
| Trends in the economic burden of chronic liver diseases and cirrhosis in the United States: 1996–2016 C Ma, AS Qian, NH Nguyen, I Stukalin, SE Congly, AA Shaheen, ... Official journal of the American College of Gastroenterology| ACG 116 (10 …, 2021 | 27 | 2021 |
| Association of immune-related adverse events, hospitalization, and therapy resumption with survival among patients with metastatic melanoma receiving single-agent or … AS Watson, S Goutam, I Stukalin, BW Ewanchuk, M Sander, DE Meyers, ... JAMA Network Open 5 (12), e2245596-e2245596, 2022 | 21 | 2022 |
| Effectiveness and safety of first-line pembrolizumab in older adults with PD-L1 positive non-small cell lung cancer: a retrospective cohort study of the Alberta immunotherapy … HAI Grosjean, S Dolter, DE Meyers, PQ Ding, I Stukalin, S Goutam, ... Current Oncology 28 (5), 4213-4222, 2021 | 19 | 2021 |
| The prognostic value of neutrophil-to-lymphocyte ratio in metastatic testicular cancer D Ribnikar, I Stukalin, PL Bedard, RJ Hamilton, M Jewett, P Warde, ... Current Oncology 28 (1), 107-114, 2020 | 15 | 2020 |
| Fourth-line therapy in metastatic renal cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC) I Stukalin, JC Wells, A Fraccon, F Pasini, C Porta, AKA Lalani, S Srinivas, ... Kidney Cancer 2 (1), 31-36, 2018 | 14 | 2018 |
| Active smoking is associated with worse prognosis in metastatic renal cell carcinoma patients treated with targeted therapies N Kroeger, H Li, G De Velasco, F Donskov, HW Sim, V Stühler, JC Wells, ... Clinical Genitourinary Cancer 17 (1), 65-71, 2019 | 13 | 2019 |
| Immune-related adverse events and survival among patients with metastatic NSCLC treated with immune checkpoint inhibitors S Cook, V Samuel, DE Meyers, I Stukalin, I Litt, R Sangha, DG Morris, ... JAMA Network Open 7 (1), e2352302-e2352302, 2024 | 10 | 2024 |
| Trends and projections in national united states health care spending for gastrointestinal malignancies (1996–2030) I Stukalin, NS Ahmed, AM Fundytus, AS Qian, S Coward, GG Kaplan, ... Gastroenterology 162 (4), 1098-1110. e2, 2022 | 10 | 2022 |
| Clinical effectiveness of second-line sunitinib following immuno-oncology therapy in patients with metastatic renal cell carcinoma: A real-world study JC Wells, S Dudani, CL Gan, I Stukalin, AA Azad, E Liow, F Donskov, ... Clinical Genitourinary Cancer 19 (4), 354-361, 2021 | 9 | 2021 |
| The physician’s Achilles heel—surviving an adverse event I Stukalin, BC Lethebe, W Temple Current Oncology 26 (6), 742-747, 2019 | 8 | 2019 |
| Impact of performance status on survival outcomes and health care utilization in patients with advanced NSCLC treated with immune checkpoint inhibitors DE Meyers, M Pasternak, S Dolter, HAI Grosjean, CA Lim, I Stukalin, ... JTO Clinical and Research Reports 4 (4), 100482, 2023 | 7 | 2023 |
| Second-line VEGF TKI after IO combination therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). I Stukalin, S Dudani, C Wells, CL Gan, SK Pal, N Dizman, T Powles, ... Journal of Clinical Oncology 38 (6_suppl), 684-684, 2020 | 7 | 2020 |
| Population-based trends in healthcare utilization and national healthcare spending on pancreatitis in North America. NS Ahmed, N Forbes, I Stukalin, S Singh, AA Shaheen, C Ma | 6 | 2021 |
